 |
|
Aspirin and Stroke
Julie E. Buring, ScD;
Charles H. Hennekens, MD;
Peter Sandercock, DM, MRCP;
Rory Collins, MBBS;
Richard Peto, FRS
Arch Neurol. 1990;47(12):1353-1354.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
In our recent article,1 we reviewed the available evidence on aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. We concluded that low-dose aspirin should be a possible adjunct, not an alternative, to coronary risk factor management and, in view of its possible side effects, should be prescribed for long-term use only by a physician or other health care provider. For primary prevention, aspirin is unlikely to be of much net benefit in young adults, except perhaps those few with genetic factors that greatly increase their risk. Among middle-aged and older adults, any decision to use aspirin should consider the cardiovascular risk profile of the patient. In most circumstances it would be reasonable to assume that aspirin will reduce nonfatal myocardial infarction (MI) by about one third, with an effect that is still favorable (but probably not as large as one third) on death
. . . [Full Text PDF of this Article]
Author Affiliations
From the Channing Laboratory, Departments of Medicine and Preventive Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Mass (Drs Buring and Hennekens); Department of Clinical Neurosciences, Western General Hospital, Edinburgh, Scotland (Dr Sandercock); and the Clinical Trial Service Unit, Radcliffe Infirmary, University of Oxford, Cambridge, England (Drs Collins and Peto).
Footnotes
Accepted for publication June 7, 1990.
Reprint requests to Channing Laboratory, Department of Medicine and Preventive Medicine, Brigham and Women's Hospital, 55 Pond Ave, Brookline, MA 02146 (Dr Buring).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
